VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China

Core Insights - VivoSim Labs has appointed JCBio for Korea and Tekon Biotech for China to distribute its NAMKind™ toxicology services, enhancing its commercial presence in the Asia-Pacific region [1][12] - The demand for human-relevant toxicology is increasing as drug developers seek faster and more reliable preclinical safety assessments [2][11] Distribution Agreements - JCBio will facilitate the deployment of NAMKind™ services in Korea, providing local coordination and scientific engagement to streamline evaluations [9][8] - Tekon Biotech aims to introduce VivoSim's NAMKind™ platforms to the Greater China market, addressing the need for accurate preclinical safety data [4][5] Market Dynamics - The in-vitro toxicology testing market in China is projected to grow from approximately $1.05 billion in 2023 to $2.26 billion by 2030, driven by increased R&D investment and evolving regulatory standards [5] - The pharmaceutical industry in China is shifting from generic manufacturing to innovative drug development, increasing the demand for predictive tools to mitigate late-stage clinical failures [7] Regulatory Alignment - Korea's regulatory body, MFDS, is aligning with the U.S. FDA's momentum towards adopting NAM-based evidence, which is expected to accelerate the acceptance of new toxicology techniques [3] Technological Advantages - VivoSim's NAMKind™ platform offers a modern approach to toxicology, designed to save time, reduce risk, and cut costs by providing human-based screening insights [10][12] - The platform is capable of delivering actionable results with a targeted 30-day turnaround time per compound, making it practical for both small and large molecules [12]